779 Views

Instructional Course

Instructional Course - Available with the Platinum and Silver packages or Individual Course Ticket

024IC - New AUA BPH Guidelines: How to Best Diagnose and How to Most Effectively and Safely Treat

Saturday, May 14, 2022

7:30 AM – 9:30 AM

Location: Room 204

Instructional Course Director(s)

Steven Abraham Kaplan, MD

Icahn School of Medicine at Mount Sinai

Instructional Course Faculty(s)

Claus Georg Roehrborn, MD

Department Chair
UT Southwestern Medical Center
KM

Kevin Thomas McVary, MD

Professor and Chair
Loyola University Medical Center
Alexis Edwin Te, MD

Weill Cornell Medical College
Lori B. Lerner, MD

Boston University School of Medicine

Learning Objectives:

Identify the role of diagnostic testing in making the accurate diagnosis of mLUTS using the new benign BPH guidelines. 1) Understand the role of diagnostic testing in making the accurate diagnosis of male LUTS using the new BPH Guidelines
Recognize the various agents available to treat mLUTS. 2) Recognize the various agents available to treat mLUTS
Identify common pathophysiological etiologies of voiding and sexual health. 3) Identify common pathophysiological etiologies of voiding and sexual health
Illustrate the impact of current therapeutic strategies on both voiding and sexual dysfunction. 4) Illustrate the impact of current therapeutic strategies on both voiding and sexual dysfunction
Identify the role of the AUA guidelines for BPH.

The diagnosis and management of male lower urinary tract symptoms (mLUTS) and benign prostatic hyperplasia (BPH) has evolved and is reflected in the 2021 AUA BPH Guidelines with important and newly changing algorithms. This course, with an outstanding faculty with first-hand experience on all the relevant clinical trials, is designed to review, discuss, and develop a coherent diagnostic and treatment strategy for men with mLUTS utilizing these new guidelines. More specifically, this will include a discussion of the new diagnostic algorithms and the use of preoperative ultrasound and pressure-flow studies. Medical therapy with both mono and combination therapy with agents such as alpha-blockers, antimuscarinics, 5-alpha reductase inhibitors, and PDE-5 inhibitors will be reviewed. With the advancement of multiple new minimally invasive surgical options including prostatic urethral lift, convective water vapor therapy and prostate expanders, and surgical options and updates on the role of electrosurgical and laser technique, urologists need to be cognizant of how these new therapies align with the current guidelines. In addition, how these agents dovetail with sexual function and testosterone replacement therapy will be highlighted. Finally, pharmacoeconomics and the impact of long-term therapy, as well as surgical outcomes, will be debated.